Market Access Strategy

Overcoming hurdles
Germany plays a special role in the market access of innovations in the healthcare sector because it is the world's third largest market for pharmaceutical and medical technology products. Innovators require a solid market access strategy at an early stage. Due to the formation of international reference prices and the relatively early market access of pharmaceutical and medical technology products in Germany. Mostly, the following central questions arise:

• How is a European market access strategy structured taking the various hurdles of national HTAs into account?
• How can a market access strategy part for Germany be developed within this framework?
• How can the global market access strategy be harmonised in the European context?

Taking the optimal path
Within the framework of market access and specifically early benefit assessment, SKC develops optimal strategies with its clients in the context of international plans and expectations. In doing so, we structure and steer the entire market access process.

The overall strategy serves as a decision-making aid and is an important guide for achieving predefined targets.

Achieving your goal with our experience
We optimize the reimbursement strategy of our clients in Europe and Germany due to our extensive experience, especially with AMNOG procedures and relevant agencies (e.g. Federal Ministry of Health, Central Association of Statutory Health Insurance (GKV-SV), Joint Federal Committee (G-BA), Institute for the Hospital Remuneration System (InEK), Institute for Quality and Efficiency in Health Care (IQWiG)).